Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

10.100
-0.300-2.88%
Volume:1.18M
Turnover:11.92M
Market Cap:10.63B
PE:-27.29
High:10.560
Open:10.500
Low:9.900
Close:10.400
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:0.67
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-18.45%
ROA:-14.45%
PB:4.72
PE(LYR):-27.29
PS:4498.13

Loading ...

Ascletis Advances ASC30: First Patient Dosed in 4,600-Subject Global Phase III Trials for Oral GLP-1 Weight-Loss Therapy

Bulletin Express
·
Yesterday

Ascletis Announces First Participant Dosed in a Global Phase Iii Clinical Program of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist Asc30 for Chronic Weight Management

THOMSON REUTERS
·
Yesterday

Ascletis Pharma - Topline Phase Iii Data Expected Q3 2028; FDA Nda by End 2028; Ema Maa Early 2029

THOMSON REUTERS
·
Yesterday

HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%

Tiger Newspress
·
Aug 26

Ascletis Pharma Slips on Expecting Deeper H1 Loss on R&D Expenses

Reuters
·
Aug 24

Ascletis Pharma Expects HY Loss of Rmb319.7 MLN

Reuters
·
Aug 21

Ascletis Pharma-B Warns of 263.5% Surge in Interim Loss to Roughly RMB 319.7 Million

Stock News
·
Aug 21

Ascletis Pharma Projects RMB319.70 Million H1 2026 Loss as R&D Spend Jumps 132.7%

Bulletin Express
·
Aug 21

Ascletis Pharma Sees H1 Loss Widening to RMB 319.7 Million

Reuters
·
Aug 21

Ascletis Pharma - Expects Loss of Rmb319.7 Mln for H1 2026, up 263.5% YoY

THOMSON REUTERS
·
Aug 21

Ascletis Pharma - Expected Hy Result as R&D Expenses Increased 132.7% to Rmb341.7 Mln, Others

THOMSON REUTERS
·
Aug 21

Ascletis Pharma (SEHK:1672) At 5x P B On Obesity Trial Momentum Looks About Right

Simply Wall St.
·
Aug 12

Ascletis Pharma Begins Obesity Drug Candidate Trial

MT Newswires Live
·
Aug 10

Ascletis Launches U.S. Phase I Trials for Potential First-in-Class Monthly Obesity Injections ASC36 and ASC36_35FDC

Bulletin Express
·
Aug 10

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: Asc36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and Asc36_35Fdc Once-Monthly Injection, a Co-Formulation of Asc36 and Glp-1R/Gipr Peptide Agonist Asc35

THOMSON REUTERS
·
Aug 10

Ascletis-B Launches Two Phase 1 Obesity Studies in the United States

Stock News
·
Aug 10

Ascletis Pharma - U.S. FDA Clears Ind Applications for Asc36 and Asc36_35Fdc

THOMSON REUTERS
·
Aug 10

Ascletis Says FDA Clears INDs for Obesity Candidates Asc36, Asc36_35fdc

Reuters
·
Aug 10

Hong Kong Market Movers: Innovative Drug Stocks Rally as Earnings Season Approaches, Medical Conferences Expected to Provide Catalysts

Stock News
·
Aug 07

Ascletis Pharma Shares Surge 5% on Global Phase 3 Trial Launch for GLP-1 Oral Drug ASC30

Deep News
·
Aug 04